AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18393298
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of lofexidine hydrochloride (1.2 mg)
Trial: 18393298
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of lofexidine hydrochloride (2.0 mg)
Trial: 15181099
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of UAG and AG
Trial: 7555620
Drug: Carbamazepine 600
RxNorm normalized name: carbamazepine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 600 mg/day
Trial: 3538486
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 100 micrograms four times daily
Trial: 26927662
Drug: CIMAvax-EGF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIMAvax-EGF vaccine
Trial: 26927662
Drug: CIMAvax-EGF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIMAvax-EGF vaccine (per-protocol setting)
Trial: 26927662
Drug: CIMAvax-EGF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIMAvax-EGF vaccine (high EGF concentration at baseline)
Trial: 24360369
Drug: Tafenoquine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 50 mg plus chloroquine
Trial: 24360369
Drug: Tafenoquine 100
RxNorm normalized name: tafenoquine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 100 mg plus chloroquine
Trial: 24360369
Drug: Tafenoquine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 300 mg plus chloroquine
Trial: 24360369
Drug: Tafenoquine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 600 mg plus chloroquine
Trial: 24360369
Drug: Primaquine 15
RxNorm normalized name: primaquine 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 15 mg for 14 days plus chloroquine
Trial: 24360369
Drug: Tafenoquine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 300 mg vs Chloroquine alone
Trial: 24360369
Drug: Tafenoquine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 600 mg vs Chloroquine alone
Trial: 18696358
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1.5 g)
Trial: 12061359
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) fluids
Trial: 7473116
Drug: Sterile balanced
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile balanced salt solution (control)
Trial: 28364461
Drug: Armodafinil (150-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil (150-250 mg)
Trial: 27053145
Drug: Optimal pressure
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal pressure ulcer-preventative care group (treatment) - regular turning every 2 hours with at least 15 minutes of tissue decompression.
Trial: 25124510
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) added to psychopharmacological treatment
Trial: 25124510
Drug: Brief structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief structured group psychoeducational intervention added to psychopharmacological treatment
Trial: 25124510
Drug: Standard clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clinical management including psychopharmacological treatment
Trial: 17244451
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 1.0 mg once daily for 168 weeks
Trial: 16279289
Drug: Open trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open trial no tablet group
Trial: 9412558
Drug: 0.15 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 IU/kg rhGH daily for 3 weeks
Trial: 3113223
Drug: Continuous nitroglycerin
RxNorm normalized name: nitroglycerin Extended Release Oral Tablet [Nitrocontin Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nitroglycerin patch therapy for 7 days
Trial: 3113223
Drug: 12-hour-daily intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour-daily intermittent nitroglycerin patch therapy for 7 days
Trial: 29847426
Drug: Intraarticular facet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular facet injections with bupivacaine and steroid
Trial: 11943558
Drug: Hormone-guided therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone-guided therapy
Trial: 6797132
Drug: Amino acid‐carbohydrate‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid‐carbohydrate‐electrolyte infusion
Trial: 6797132
Drug: Carbohydrate‐electrolyte infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte infusion
Trial: 31539599
Drug: Engage (Coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engage (Coping Skills Training and Acceptance and Commitment Therapy)
Trial: 25549933
Drug: Acupuncture (100%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (100% post-treatment expectations)
Trial: 25549933
Drug: Acupuncture (0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (0% post-treatment expectations)
Trial: 20923463
Drug: Glycerol ointment
DrugBank: Glycerin (DB09462)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycerol ointment
Trial: 19465858
Drug: Conventional, nonbiologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional, nonbiologic pharmacotherapy
Trial: 15374727
Drug: Sequential transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential transdermal estrogen‐progestin therapy
Trial: 8295841
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of child behavioral and parental role information
Trial: 3987783
Drug: Previous three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous three drug regimens (beta blocker and two other antihypertensive agents)
Trial: 28910848
Drug: Misoprostol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (50 µg)
Trial: 27107394
Drug: Iron tablet
RxNorm normalized name: PNV-Iron Tablet
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron tablet (ferrous sulfate, 200 mg)
Trial: 27107394
Drug: Iron infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron infusion
Trial: 20413516
Drug: Benfotiamine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine (900 mg/day) for 12 weeks
Trial: 17047160
Drug: Insulin clamp
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin clamp at 5 mU x m(-2) x min(-1)
Trial: 17047160
Drug: Insulin clamp
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin clamp at 30 mU x m(-2) x min(-1)
Trial: 17047160
Drug: Insulin clamp
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin clamp at 55 mU x m(-2) x min(-1)
Trial: 17047160
Drug: Insulin clamp
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin clamp at 105 mU x m(-2) x min(-1)
Trial: 10908888
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (IFNbeta-1a) 30 mcg IM once weekly
Trial: 8956922
Drug: Intracarotid amobarbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracarotid amobarbital procedure (IAP) with 125 mg sodium amytal injection
Trial: 1372470
Drug: Topical 5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5‐fluorouracil
Trial: 31320446
Drug: Efpeglenatide 1
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 1 mg, 2 mg, 3 mg, 4 mg once weekly
Trial: 31320446
Drug: Efpeglenatide ≥1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide ≥1 mg
Trial: 31320446
Drug: Efpeglenatide 3
RxNorm normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efpeglenatide 3 mg, 4 mg once weekly
Trial: 24678813
Drug: Goserelin, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin, 2 monthly doses (n = 18)
Trial: 24678813
Drug: Goserelin, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin, 3 monthly doses (n = 18)
Trial: 24678813
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, no treatment (n = 32)
Trial: 17180572
Drug: Hydration therapy
RxNorm normalized name: Neosporin Daily Hydration Therapy SPF 20 Lip Balm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration therapy only
Trial: 9630824
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1 gm mycophenolate mofetil
Trial: 7524456
Drug: High-dose thromboplastin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thromboplastin
Trial: 7524456
Drug: High-dose thrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thrombin
Trial: 7524456
Drug: High-dose thromboplastin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thromboplastin and high-dose thrombin measurements
Trial: 31972655
Drug: Remimazolam continuous
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam continuous intravenous infusion (5 mg/min for 5 min, 3 mg/min for 15 min, 1 mg/min for 15 min)
Trial: 31972655
Drug: Remimazolam continuous
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam continuous intravenous infusion
Trial: 29548834
Drug: Standardized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized oral consent and written information sheet (Group 2)
Trial: 29548834
Drug: Standardized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized oral informed consent (Group 1)
Trial: 23882695
Drug: Occlusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusion therapy for amblyopia (6 hours/day in MOTAS; randomized to 6 or 12 hours/day in ROTAS)
Trial: 23882695
Drug: Occlusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusion therapy on weekends
Trial: 23882695
Drug: Occlusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusion therapy with less frequent attendance
Trial: 23882695
Drug: Occlusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusion therapy with prolonged treatment duration
Trial: 23882695
Drug: Different subpopulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different subpopulations of patch day doses
Trial: 18982782
Drug: Propofol TCI
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol TCI (5 ng L(‐1) remifentanil, 2.8 microg mL(‐1) propofol)
Trial: 17083356
Drug: Shrimp-derived glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shrimp-derived glucosamine (1,500 mg)
Trial: 17083356
Drug: Synthetic glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic glucosamine (1,500 mg)
Trial: 11881630
Drug: Clenching without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clenching without implant support
Trial: 11881630
Drug: Clenching with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenching with implant support
Trial: 7551918
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy combined with preoperative radiation therapy
Trial: 1693711
Drug: Felodipine added
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine added to beta-blocker
Trial: 1646621
Drug: Felodipine monotherapy
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine monotherapy
Trial: 31934950
Drug: Fractional microablative
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional microablative CO2 laser treatment
Trial: 31134707
Drug: Dietitian Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietitian Group (DG) - advised by dietitians in six weekly face-to-face behavioural therapy sessions
Trial: 25814318
Drug: Pinocembrin 20-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinocembrin 20-150 mg single ascending doses
Trial: 25814318
Drug: Pinocembrin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinocembrin 60 mg multiple doses
Trial: 23479384
Drug: Cetuximab (week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (week 1: 400 mg/m²; subsequent weeks: 250 mg/m²) plus cisplatin (100 mg/m², day 1) and 5-fluorouracil (1000 mg/m²/day, 24-h infusion, days 1-4)
Trial: 21849487
Drug: Reduced-dose bortezomib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose bortezomib, thalidomide plus dexamethasone (vtD)
Trial: 15480324
Drug: Levocetirizine 5
RxNorm normalized name: Levocetirizine 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 5 mg/d
Trial: 11709567
Drug: Combined-modality therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality therapy (CMT) consisting of three cycles of doxorubicin and vinblastine followed by subtotal lymphoid irradiation (STLI)
Trial: 12698396
Drug: Heparin-coated extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated extracorporeal circuit
Trial: 8441570
Drug: Intranasal midazolam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal midazolam, 0.4 mg/kg
Trial: 31789965
Drug: Protective ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective ventilation (Low tidal volume of 6 ml/kg predicted body weight during two-lung ventilation and 3 ml/kg predicted body weight during one-lung ventilation with 5 cmH2O positive end-expiratory pressure)
Trial: 31789965
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation (Intermediate tidal volume of 10 ml/kg predicted body weight during two-lung ventilation and 5 ml/kg predicted body weight during one-lung ventilation with no positive end-expiratory pressure)
Trial: 30413407
Drug: Alpelisib plus
RxNorm normalized name: alpelisib
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpelisib plus fulvestrant endocrine therapy
Trial: 22984204
Drug: Levofloxacin-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin-containing quadruple therapy (EBTL group): 40 mg of esomeprazole twice daily, 300 mg of bismuth subcitrate four times daily, 500 mg of tetracycline four times daily, and 500 mg of levofloxacin once daily for 10 days (n = 76)
Trial: 22984204
Drug: High-dose metronidazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metronidazole-based quadruple therapy (EBTM group): 40 mg of esomeprazole twice daily, 300 mg of bismuth subcitrate four times daily, 500 mg of tetracycline four times daily, and 500 mg of metronidazole four times daily for 10 days (n = 74)
Trial: 22984204
Drug: Levofloxacin-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin-containing quadruple therapy (EBTL group)
Trial: 22984204
Drug: High-dose metronidazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metronidazole-based quadruple therapy (EBTM group)
Trial: 22073795
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (60 mg elemental iron)
Trial: 15046441
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (historical control group)
Trial: 8915150
Drug: Diphencyprone (DPCP)
DrugBank: Diphencyprone (DB12173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphencyprone (DPCP) treatment, 2% solution, applied once a week for at least 3 months, up to 1 year.
Trial: 1347854
Drug: Artesunate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (600 mg over 5 days)
Trial: 1347854
Drug: Mefloquine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (750 mg then 500 mg 6 h later)
Trial: 8701045
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of artesunate and mefloquine
Trial: 2859204
Drug: Triprolidine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine (2.5 mg and 5 mg)
Trial: 2957398
Drug: Isotretinoin 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 0.05% gel
Trial: 11132613
Drug: Amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5-10 mg o.d. (n = 15)
Trial: 11132613
Drug: Felodipine 5-10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5-10 mg o.d. (n = 15)
Trial: 11132613
Drug: Lacidipine 4-6
RxNorm normalized name: lacidipine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine 4-6 mg o.d. (n = 15)
Trial: 11132613
Drug: Manidipine 10-20
RxNorm normalized name: manidipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine 10-20 mg o.d. (n = 15)
Trial: 9163255
Drug: Furosemide-containing suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide-containing suppositories (Massa Estarinum 299)
Trial: 9163255
Drug: Furosemide Sodium
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide Sodium suppositories
Trial: 1590228
Drug: Pirenzepine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (2 mg)
Trial: 1590228
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (2 ml)
Trial: 28765003
Drug: Vaccine (VAC)
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (VAC)
Trial: 15190963
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of a monoclonal anti-IL-6 Ab (B-E8)
Trial: 11477830
Drug: Acanthopanax Injection
RxNorm normalized name: Manyprickle Acanthopanax
DrugBank: Eleuthero (DB14303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acanthopanax Injection (AI) 60-80 ml added to 500 ml of 0.9% normal saline, given intravenously once a day for 14 days
Trial: 11477830
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 500 ml of dextra-40 given intravenously once a day for 14 days
Trial: 11477830
Drug: Acanthopanax Injection
RxNorm normalized name: Manyprickle Acanthopanax
DrugBank: Eleuthero (DB14303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acanthopanax Injection (AI) 10 ml given intravenously once daily for 7 days in rabbit model
Trial: 11477830
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 10 ml of normal saline given intravenously once daily for 7 days in rabbit model
Trial: 8681496
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g x 3 for two weeks)
Trial: 8681496
Drug: Propafenone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (300 mg x 3 for two weeks)
Trial: 8681496
Drug: Propafenone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone + L-carnitine (300 mg x 3 + 2 g x 3 at the second week)
Trial: 8681496
Drug: Mexiletine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (200 mg x 3 for two weeks)
Trial: 8681496
Drug: Mexiletine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine + L-carnitine (200 mg x 3 + 2 g x 3 at the second week)
Trial: 31633865
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg controlled-release oral morphine
Trial: 28698334
Drug: Monthly text
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly text messages reminding them to test for HIV/STIs
Trial: 26504123
Drug: Laser acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser acupuncture combined with pharmacological therapy (morphine and phenobarbital)